Key terms
About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BMY news
Today
1:37am ET
Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results
Yesterday
5:52pm ET
Gerald Storch Exits, Bristol-Myers Squibb Board Shrinks
Yesterday
5:15am ET
Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition
Mar 15
6:30pm ET
Bristol Myers, 2seventy Bio: FDA’s ODAC votes in favor of Abecma
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 15
5:11am ET
Bristol Myers announces FDA grants accelerated approval of Breyanzi
Mar 14
7:16am ET
Hold Rating on Bristol-Myers Squibb Amid Concerns Over Abecma’s Efficacy and Safety
Mar 12
6:59pm ET
Bristol Myers’ repotrectinib receives FDA orphan designation
Mar 12
8:37am ET
Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
Mar 11
2:48pm ET
Bristol-Myers Squibb (NYSE:BMY) Shrugs off Analyst Cut
Mar 11
12:43pm ET
Bristol Myers downgraded to Hold from Buy at Societe Generale
Mar 07
2:26pm ET
Bristol Myers reports FDA approves Opdivo for first-line metastatic UC treatment
Mar 05
11:39am ET
Healthcare Stocks Mostly In Retreat After New Task Force Announced
Mar 05
7:32am ET
2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4
Feb 29
7:02am ET
Bristol Myers’ ozanimod shows efficacy and safety in multiple sclerosis trial
Feb 27
6:02am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Krystal Biotech (KRYS) and Bristol-Myers Squibb (BMY)
Feb 27
5:58am ET
Bristol-Myers Squibb: Balancing Growth Prospects Against Market Challenges and Uncertainties
Feb 26
11:45am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 26
9:17am ET
Bristol Myers completes acquisition of RayzeBio
Feb 26
4:55am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 23
7:49am ET
C4 Therapeutics price target raised to $13 from $12 at Stifel
Feb 23
7:05am ET
Bristol Myers announces expiration of tender offer for RayzeBio
Feb 23
7:00am ET
Bristol Myers announces positive CHMP opinion for Reblozyl
Feb 22
4:40pm ET
Bristol-Myers Squibb’s $11 Billion Notes Issuance for Acquisitions
Feb 22
7:18am ET
Immunocore enters trial collaboration, supply agreement with Bristol Myers
Feb 22
6:34am ET
Karuna Therapeutics reports Q4 EPS ($3.01), consensus ($2.65)
Feb 21
12:10pm ET
Truist biotech analysts hold an analyst/industry conference call
Feb 20
7:11am ET
Aurora Cannabis CFO Glen Ibbott to step down, Simona King to succeed
Feb 20
7:01am ET
Bristol Myers says FDA accepts sNDA for KRAZATI in combination with cetuximab
Feb 15
5:14pm ET
Bristol-Myers Squibb Announces New Senior VP and Controller
Feb 14
4:44pm ET
Bristol-Myers Squibb Warns Against Tutanota’s Mini-Tender Offer
No recent news articles are available for BMY
BMY Financials
Key terms
Ad Feedback
BMY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BMY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range